Humalda JK, Yeung SMH, Geleijnse JM, et al. - Researchers conducted a post hoc analysis of a dietary controlled randomized, blinded, placebo-controlled crossover trial to examine the impacts of potassium or sodium supplementation on bone mineral parameters, including fibroblast growth factor 23 (FGF23). Capsules containing potassium chloride (3 g/d), sodium chloride (3 g/d), or placebo were obtained by prehypertensive individuals not using antihypertensive medication (n = 36). According to findings, potassium supplementation resulted in a decline in FGF23, which was followed by an increase in plasma phosphate and decreased excretion of calcium. Sodium supplementation decreased FGF23 but this was followed by a decrease in phosphate and an increase in the excretion of fractional calcium. The findings indicate distinct effects of the intake of potassium and sodium on bone mineral parameters, including FGF23.